Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncoimmunology. 2012 Oct 1;1(7):1181-1182.

Interleukin-2 treatment of tumor patients can expand regulatory T cells.

Author information

  • 1Genomics and Immunoregulation; LIMES-Institute; University of Bonn; Bonn, Germany.

Abstract

Augmented numbers of regulatory T cells contribute to the overall immunosuppression in tumor patients. Interleukin-2 has been widely used in the clinics in anticancer therapy, yet evidence has accumulated that the major drawback, limiting clinical efficacy, is the expansion of regulatory T cells, which aggravates immunosuppression.

PMID:
23170272
[PubMed]
PMCID:
PMC3494638
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk